Mironid

Mironid announced $46M in Series B financing on August 5, 2026. Mironid raised a $46 million Series B supported by the Scottish National Investment Bank and existing investors to advance clinical development of its ADPKD treatment.

Round details

The financing includes backing from Scottish National Investment Bank, Roche Venture Fund, Epidarex Capital, Sofinnova Partners, BioGeneration Ventures, University of Strathclyde. The company did not publish a valuation with the announcement.

• Round: Series B
• Capital announced: $46M

How the company plans to use the capital

Proceeds will advance the clinical development of the company’s first-in-class LoAc small molecule for Autosomal Dominant Polycystic Kidney Disease (ADPKD). The announcement did not specify a more detailed breakdown of spending.

Why this matters for GTM teams

The round included one new investor, the Scottish National Investment Bank, alongside five existing investors, and the company described ADPKD as the most common hereditary kidney disorder.

Fresh capital is often an operational signal rather than a buying signal by itself. Teams should validate the company’s hiring pattern, product launches, geographic expansion, and technology priorities before choosing the message and timing of outreach.

Source and methodology

This report is based on the company’s announcement and records the disclosed amount, round, investors, location, and stated use of funds. SalesTools Research does not estimate undisclosed valuation or revenue figures.

Primary source: Mironid Series B announcement.